Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|121|22|4071-4079

ISSN： 0008-543X

Source： Cancer, Vol.121, Iss.22, 2015-11, pp. : 4071-4079

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer

By Abern Michael R.   Terris Martha K.   Aronson William J.   Kane Christopher J.   Amling Christopher L.   Cooperberg Matthew R.   Freedland Stephen J.  

Cancer, Vol. 120, Iss. 11, 2014-06 ,pp. : 1656-1662

Blackwell Publishing

Access to resources Recommend Favorite

Long-term goserelin does not deprive prostate cancer patients

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 499, 2006-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Staging, cytoreduction and chemotherapy improve long-term outcomes in patients with ovarian cancer

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 22, Iss. 8, 2006-08 ,pp. : 10-13

Adis International

Access to resources Recommend Favorite

Moreira DM, Nickel JC, Gerber L, Muller RL, Andriole GL, Castro-Santamaria R and Freedland SJ. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: Results from the REDUCE study. Cancer. 2014;120:190-196.

By  

Cancer, Vol. 121, Iss. 23, 2015-12 ,pp. : 4271-4271

Blackwell Publishing

Access to resources Recommend Favorite

Long-term anticoagulation reduces cancer risk?

By  

Inpharma, Vol. 1, Iss. 1245, 2000-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite